Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 MVXGeY5kfGmxbjDBd5NigQ>? MljpNE4yNTNyIN88US=> Ml;KOFghcA>? NISySVdqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? MXGyOlUyOzF5Mh?=
H460 MWfGeY5kfGmxbjDBd5NigQ>? MX:wMlEuOzBizszN NGTNb241QCCq MYHpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MYmyOlUyOzF5Mh?=
HKESC-2 NIm4VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTtblVsOjEEoN88US=> NH;yXFc1QMLiaNMg M1XpOpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? NGDVbXQzPjR5NE[5Ny=>
CaES-17 M3fyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOyNOKh|ryP M1rYb|Q5yqCqwrC= M1\FWpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? M3rzcFI3PDd2Nkmz
HKESC-2 MofFRZBweHSxc3nzJGF{e2G7 NU\neWVpOjEEoN88US=> MoDVOFjDqGkEoB?= MnrNdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NGqxUVUzPjR5NE[5Ny=>
CaES-17 MkmxRZBweHSxc3nzJGF{e2G7 NIPvcIczOMLizszN MVK0POKhcMLi NYHlOlhkemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? M3;rdlI3PDd2Nkmz
A549 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jwOFUuOTZyIN88US=> MUW0POKhcMLi MoXFSG1UVw>? M1\s[GlEPTB;MU[zMlQh|ryP M1;wdFI3PDZ2NkSz
HCC827 NXPQT5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\qfpU2NTF4MDFOwG0> MWe0POKhcMLi MlXISG1UVw>? M2LsbGlEPTB;NkmuNkDPxE1? MW[yOlQ3PDZ2Mx?=
A549 MmfoRZBweHSxc3nzJGF{e2G7 MUK4NEDDvU1? MWm0POKhcMLi NH;EdYRFVVOR M33DcYlv\HWlZYOgZZBweHSxc3nz NELoUXQzPjR4NE[0Ny=>
HCC827 Mmq4RZBweHSxc3nzJGF{e2G7 NFWyfmk5OCEEtV2= M2DZdVQ5yqCqwrC= NFLmS2pFVVOR NYLLeVg{cW6mdXPld{BieG:ydH;zbZM> MlfSNlY1PjR4NEO=
SGC-7901/DDP NXOwV|FGTnWwY4Tpc44hSXO|YYm= MnPTNVDDqML3TR?= NITiUZozPCCq MXzpcohq[mm2czDjfYNtd2:6eXflcoF{\S1{IHHu[EBRNWeueXPvdJJwfGWrbjDlfJBz\XO|aX;u MYeyOlQxPzZ3Mx?=
SGC-7901  MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLXOXFYOjUEoHlCpC=> MkKwTWM2OD1zMUWuNFgh|ryP NHTVWHgzPjRyN{[1Ny=>
SGC-7901/DDP NHvYVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nsUlI1yqCqwrC= NXjWfVY5UUN3ME2zOU41PSEQvF2= NWTPRpNqOjZ2MEe2OVM>
SGC-7901/DDP MmrVRZBweHSxc3nzJGF{e2G7 NV3IcJNCOTEEoNM1US=> M2jVOVI1KGh? M3;sSYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> MWOyOlQxPzZ3Mx?=
SGC-7901/DDP MWTGeY5kfGmxbjDBd5NigQ>? NUXYUnZpOTEEoNM1US=> MVyyOEBp M1nRbIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi NW[2d|lWOjZ2MEe2OVM>
SGC-7901/DDP M4fudmZ2dmO2aX;uJGF{e2G7 MYKxNOKhyrWP NV\DUmdqOjRiaB?= NUT5UJlJ[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv NYLlXlJmOjZ2MEe2OVM>
H357 NWL1emo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLyO{42NzFyIN88US=> M2fIOVQ5KGh? MX3EUXNQ M1rUb4lvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> M3K1OFI3ODB7OEe0
TAF MU\GeY5kfGmxbjDBd5NigQ>? MYqxNOKhyrWP MWG3JIQ> M4HBWYFn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW| NF\tU5QzPTl6N{GyOy=>
TAF M2Pu[mZ2dmO2aX;uJGF{e2G7 MYWxNOKhyrWP MXGzNE0yOjBibXnu MW\wc49zdHliYX\m[YN1eyCmQXv0JJBpd3OyaH;yfYxifGmxbjDjc45{\XG3ZX70JJRwKEWJRjDzbYdv[Wyrbne= MVuyOVk5PzF{Nx?=
TAF NUDuSm9CTnWwY4Tpc44hSXO|YYm= NVH0[pFHOTEEoNM1US=> NVHV[GNwPDhiaB?= NI\0NJlqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M{jnfFI2QTh5MUK3
PANC-1 NEH2SphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rNTFIxNzZyL{GwNEDPxE1? M1jnTFI1NzR6L{eyJIg> MmC0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHX4NlEzPTl5M{C2Ni=>
PANC-1 MU\GeY5kfGmxbjDBd5NigQ>? M2WxWlIxNzZyL{GwNEDPxE1? MVKyOEBp Mk\kZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mn30NlU6PzNyNkK=
HeLa  NGfZXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\5NlDDqM7:TdMg MofYNlTDqGh? MYnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M2H3cVI2PzdyNEKz
SACC-83 NW\uZXN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmyNOKh|ryPwrC= NGW2d2ozPMLiaB?= M3HIRYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NFTqWpUzPTd5MESyNy=>
HeLa  MmnkRZBweHSxc3nzJGF{e2G7 M2T0T|IxyqEQvF5CpC=> NVLiSVk4OjUEoHi= NXXO[mxy\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? NXqyNW1EOjV5N{C0NlM>
SACC-83 M1nRcWFxd3C2b4Ppd{BCe3OjeR?= NX64NG9bOjEEoN88UeKh NFjuZogzPMLiaB?= NGr6[VBmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ NULMeoZGOjV5N{C0NlM>
HeLa  NEHO[INHfW6ldHnvckBCe3OjeR?= M1flTVIxNzRyL{iwJO69VQ>? MV:yOOKhcA>? MX71dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NWrWNYhUOjV5N{C0NlM>
SACC-83 MmLJSpVv[3Srb36gRZN{[Xl? M4LkUVIxNzRyL{iwJO69VQ>? MVyyOOKhcA>? NVTsXoNjfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? MlrDNlU4PzB2MkO=
HLCZ01 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILyNnMx6oDVNkFCpOK2VQ>? NYTRe2RnPDhiaB?= MV\EUXNQ NWO4S|E3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1K2OFI2PzJ2OEm5
HLCZ01 NF7DcWZHfW6ldHnvckBCe3OjeR?= NXPIPYdkPDEEoN88US=> NFnVNmUzPCCq MojkSG1UVw>? M3f5colv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MUWyOVczPDh7OR?=
HLCZ01 NX3lVXhsSXCxcITvd4l{KEG|c3H5 MlKxOFDDqM7:TR?= Ml\WNlQhcA>? NXe1c3pxTE2VTx?= MkTn[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y MWOyOVczPDh7OR?=
HLCZ01 MlfkSpVv[3Srb36gRZN{[Xl? M4jLN|QxyqEQvF2= M1nQbFI1KGh? NXjnOGZsTE2VTx?= M{XmSIlv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> MXKyOVczPDh7OR?=
MGC803 M{PGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqwMVYxKM7:TR?= MWW3NkBp NHS5RnBKSzVyPUS3MlI26oDLwsJihKk3NjR|IN88US=> M{PjNFI2PzBzM{e4
SGC7901 NH7TfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMVYxKM7:TR?= M3fRS|czKGh? M1flW2lEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN NEXq[Y4zPTdyMUO3PC=>
MGC803 NV;LXlVmTnWwY4Tpc44hSXO|YYm= NV;MeWNuPDEEoN88US=> MV[4M|E3NzJ2IHi= M33QbZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NVfpPW5JOjV5MEGzO|g>
SGC7901 NV3zcI42TnWwY4Tpc44hSXO|YYm= MVe0NOKh|ryP NF3qeVU5NzF4L{K0JIg> MlvweZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u NEDaZZEzPTdyMUO3PC=>
MCF-7  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGxM|ExKM7:TR?= NHvtRWY4OiCq M4G3UmROW09? NVLsfoIx\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= MWeyOVY3PzVzMB?=
MDA-MB-231  NIrw[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjLVINvOS9zMDFOwG0> NV21cZV{PzJiaB?= M{nrOGROW09? MkjH[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? MV6yOVY3PzVzMB?=
MDA-MB-231 MnLKSpVv[3Srb36gRZN{[Xl? M{L1elAuPDBiwsXN NHfGUpQ1NTJ2IHi= Mn\ObY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MX:yOVU5PzN{OR?=
MCF-7 MoXySpVv[3Srb36gRZN{[Xl? MmLONE01OCEEtV2= MYq0MVI1KGh? Moi4[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? NH\uRZEzPTV6N{OyPS=>
MCF7-MX  MVzGeY5kfGmxbjDBd5NigQ>? NXPPfZVIOC12MDFCuW0> NVnFOmI1PC1{NDDo NVfjbHRM\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= MV:yOVU5PzN{OR?=
MDA-MB-231 MUPGeY5kfGmxbjDBd5NigQ>? M3PyOlAuPDBiwsXN M3zMZ|QuOjRiaB?= M2TBU5N1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= MWSyOVU5PzN{OR?=
A2780 M3TCOGZ2dmO2aX;uJGF{e2G7 NVHUV3pyPS9zMD:xOUDPxE1? M1jJW|Q5KGh? NF\jR5Vl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1rQOVI2PDJ2OEm4
SKOV3  MonDSpVv[3Srb36gRZN{[Xl? NVz0eWYxPS9zMD:xOUDPxE1? NXuybmx6PDhiaB?= Ml\C[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NH[zN4kzPTR{NEi5PC=>
A2780 MUTGeY5kfGmxbjDBd5NigQ>? NWnY[o14PS9zMD:xOUDPxE1? MXe0PEBp MXrlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv M{ToVVI2PDJ2OEm4
SKOV3  MULGeY5kfGmxbjDBd5NigQ>? NG\0dow2NzFyL{G1JO69VQ>? NGnzfnI1QCCq M2\2UYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? Mn61NlU1OjR6OUi=
A2780 NH70RoZHfW6ldHnvckBCe3OjeR?= M4PnOVUwOTBxMUWg{txO M3u1blQ5KGh? MknB[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw MorKNlU1OjR6OUi=
SKOV3  MUfGeY5kfGmxbjDBd5NigQ>? MYK1M|ExNzF3IN88US=> M{T2R|Q5KGh? MorS[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw NYq4eo5GOjV2MkS4PVg>
A2780 NYKxS4NUTnWwY4Tpc44hSXO|YYm= MnTPOU8yOC9zNTFOwG0> NITqZZQyKGh? MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUiyOVQzPDh7OB?=
SKOV3  MXHGeY5kfGmxbjDBd5NigQ>? M1\mW|UwOTBxMUWg{txO MmS4NUBp MnzzbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWHySVdXOjV2MkS4PVg>
HCT-15 MU\GeY5kfGmxbjDBd5NigQ>? MYOxNE02OCEQvF2= Moi4Ok0{PiCq M4e1RYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MVGyOVIyQDB{OB?=
HT-29  NGHBOmlHfW6ldHnvckBCe3OjeR?= NIrsSlUyOC13MDFOwG0> MnPLOk0{PiCq Mm\3bY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NILrOYczPTJzOECyPC=>
HSC3  NXvrPYM2S2WubDDWbYFjcWyrdImgRZN{[Xl? NEXtUngx6oDVNECg{txO M1W1clQ5KGh? NXe1OYNHUUN3ME2yOU42yrFzLke4NEDPxE1? M4PyelI2OTl6N{i5
HSC3  M4[1R2Fxd3C2b4Ppd{BCe3OjeR?= MWGyOUDPxE1? NUOxVWJiPDhiaB?= MYDpcoR2[2W|IHHwc5B1d3Orcx?= NI\1d2ozPTF7OEe4PS=>
HSC3  NEDrcVBHfW6ldHnvckBCe3OjeR?= NWrneZhOOjVizszN M1HsfVQ5KGh? MWDlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV MkHCNlUyQTh5OEm=
HSC3  MU\GeY5kfGmxbjDBd5NigQ>? NU\Uc2RYOjVizszN NH\KZpQ1QCCq NHzQWnNqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> MW[yOVE6QDd6OR?=
HSC3  NEP2fmlHfW6ldHnvckBCe3OjeR?= NHjJZXIzPSEQvF2= NIT1O5Y4OiCq M2qyS4Rm[3KnYYPld{BOVVBvMjDhcoQhVU2SLUmgdJJwfGWrboRCpC=> M{TKN|I2OTl6N{i5
201T  NUPOenRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp MVTEUXNQ NV3DSHpkUUN3ME20PE43KML3TR?= M2jSc|I2ODV5OUSx
273T M2XTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TXdVczKGh? MoHaSG1UVw>? MkG3TWM2OD16MD61JOK2VQ>? MmDuNlUxPTd7NEG=
Hep-2 NYfFPW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q5VVMxNzVyL{GwNEDPxE1? NHvsdHgyOi9{ND:zOk81QCCq NELtPWJFVVOR NXTuOXllcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NXrEcXFCOjR7OUi1OlQ>
Hep-2 NFixVYlCeG:ydH;zbZMhSXO|YYm= NX7sUlF[PTBizszN M3;LPFAuPDhiaB?= MnLESG1UVw>? M2TaeIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy MonUNlQ6QTh3NkS=
Hep-2 NVLiWHRHTnWwY4Tpc44hSXO|YYm= M2fSbVUxKM7:TR?= M17v[lAuPDhiaB?= MnTaSG1UVw>? M1nwU5Jm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 M4GzNlI1QTl6NU[0
Hep-2 NXXsbnBtTnWwY4Tpc44hSXO|YYm= Ml3JOVAh|ryP NHHHfGMxNTR6IHi= MUnEUXNQ MkfD[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ> NYn1XWxEOjR7OUi1OlQ>
SGC-7901 NYrDfWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNE82OC9zMECg{txO NXjHeVFFOjRxNEivO|IhcA>? NWHRXFE6TE2VTx?= M1X4WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFrHXGgzPDl7Mkm1PC=>
MKN-45 M2jlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPoeVQyOC93MD:xNFAh|ryP MY[yOE81QC95MjDo NE\4b5RFVVOR NU\PWZNQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Ml[3NlQ6QTJ7NUi=
SGC-7901 NXrleJBTTnWwY4Tpc44hSXO|YYm= MWCxNE82OC9zMECg{txO MX[0PEBp MYPEUXNQ M3XHdYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M17EWVI1QTl{OUW4
MKN-45 NEnxUG5HfW6ldHnvckBCe3OjeR?= MXKxNE82OC9zMECg{txO M1TtelQ5KGh? MkfXSG1UVw>? MUfkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXuyOFk6Ojl3OB?=
C666-1 MWPDfZRwfG:6aXPpeJkhSXO|YYm= NGjHWo0zOC16MDFOwG0> NVGycGZjOjRiaB?= NVvKflk4\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MVGyOFg2PDh|OB?=
CNE-1 M3j5dGN6fG:2b4jpZ4l1gSCDc4PhfS=> MUiyNE05OCEQvF2= MWmyOEBp M{f6UoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NGjDT5UzPDh3NEizPC=>
CNE-2 MWjDfZRwfG:6aXPpeJkhSXO|YYm= NWnKdIFVOjBvOECg{txO NUXWfZZOOjRiaB?= NHnlUI1l\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh M{DXO|I1QDV2OEO4
C666-1 NWDqfW04S3m2b4TvfIlkcXS7IFHzd4F6 MofQOlAh|ryP NH[xV404KGR? NWPVSGky\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> MYKyOFg2PDh|OB?=
CNE-1 NVzQO4d4S3m2b4TvfIlkcXS7IFHzd4F6 M1znO|YxKM7:TR?= NV\BZ3oxPyCm MVzlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= MoSyNlQ5PTR6M{i=
SNU-1041 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nrfFAuPDBizszN Mnn0OFghcA>? M1jlOYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NYKxSo9lOjR4OUK3NFM>
SNU-1041 NETscmpHfW6ldHnvckBCe3OjeR?= MlTCNlAwOzBizszN MkTBOEBp NXvrWpQxcW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB? M{LQUFI1Pjl{N{Cz
SNU-1041 NVz1RoxlTnWwY4Tpc44hSXO|YYm= NIjnc48xNTRyIN88US=> MV:0JIg> NWLzPHdJfXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= MmXCNlQ3QTJ5MEO=
SGC-7901 NV3iWIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLMOVAuOTJ3IN88US=> NVu2THV3OjRxNEivO|IhcA>? NVrwfnRicW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MmO0NlQ3PzZ|OUS=
SGC-7901 MWfBdI9xfG:|aYOgRZN{[Xl? M3TrUFExOCEQvF2= M2TFVVczKGh? NHi2XVJqdmS3Y3XzJIFxd3C2b4Ppdy=> NF3DN|AzPDZ5NkO5OC=>
SGC-7901 MmnVSpVv[3Srb36gRZN{[Xl? M1LhPVc2NzFyMD:xNlUh|ryP MnXRNlQwPDhxN{KgbC=> M2P0Z4lv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy NYrMN5QzOjR4N{[zPVQ>
LMeC  NHfFSJBHfW6ldHnvckBCe3OjeR?= M4P4dlIxNzVyIN88US=> M3HXOVQ5KGh? NYfNXmRY\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEORWD2yJJBzd3SnaX6= NV7B[FZROjR4NU[3OFY>
CMeC-1 MmLMR4VtdCCYaXHibYxqfHliQYPzZZk> MojZNlAwPTBizszN MnfIOFghcA>? MlnBbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlLoNlQ3PTZ5NE[=
LMeC NIH1V4FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1Pw[|IxNzVyIN88US=> M1[wblQ5KGh? M4HR[YlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWqyOFY2Pjd2Nh?=
CMeC-1 M3;IbmZ2dmO2aX;uJGF{e2G7 M1fMOVIxNzVyIN88US=> M1e0elQ5KGh? NYq2UZlIcW6mdXPld{BIOS2VIHHydoV{fA>? NXnEcVljOjR4NU[3OFY>
LMeC M{\LRmZ2dmO2aX;uJGF{e2G7 MVeyNE82OCEQvF2= NHX1VWg1QCCq NYPqUI1ncW6mdXPld{BIOS2VIHHydoV{fA>? NVnS[JlXOjR4NU[3OFY>
CMeC-1 NYXmVFhiTnWwY4Tpc44hSXO|YYm= M2ryPVIxNzVyIN88US=> NHj3N4I1QCCq M4jlWYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYGyOFY2Pjd2Nh?=
LMeC MoXVSpVv[3Srb36gRZN{[Xl? MnjKNlAwPTBizszN NWG3PGpJPDhiaB?= M{HPUoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MV:yOFY2Pjd2Nh?=
CMeC-1 NFTROFBHfW6ldHnvckBCe3OjeR?= Ml\ZNlAwPTBizszN NEiyU2E1QCCq NEnnT41qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MnLINlQ3PTZ5NE[=
LMeC MkjuSpVv[3Srb36gRZN{[Xl? NXjibpI4OjBxNUCg{txO NWfZUVQ6PDhiaB?= M2fIW4lv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> M{TOTVI1PjV4N{S2
OVCAR-3 M{TOV2NmdGxiVnnhZoltcXS7IFHzd4F6 MYCxNEDDvU1? MVOxJIg> NXPUbWFz\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MWWyOFUzODJ{Nx?=
OVCAR-3 Mn7TRZBweHSxc3nzJGF{e2G7 MX2xNEDDvU1? MnzYNUBp Mn23dJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh NFHuNpIzPDV{MEKyOy=>
OVCAR-3 MVzGeY5kfGmxbjDBd5NigQ>? M2P4SVExKML3TR?= NFXxc48yKGh? NHO0b41mdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=> NViyfmJwOjR3MkCyNlc>
OVCAR-3 MUXGeY5kfGmxbjDBd5NigQ>? NEfm[lYyOCEEtV2= NFz1eHMyKGh? NFLSdZdld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> NX7IWlNPOjR3MkCyNlc>
OVCAR-3 NWGzN2R6TnWwY4Tpc44hSXO|YYm= M{nGPFExKML3TR?= MljJNUBp M2SwUolvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v M2\YN|I1PTJyMkK3
CF33 NYPWOINjTnWwY4Tpc44hSXO|YYm= MmPxNVAxKM7:TR?= NVHmS2lVOjRiaB?= MWHpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>? M2fGcFI1PTB|N{iy
CF33 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH72S2YyOC1zMECg{txO M3\I[VAuPCCm M{XsRYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlyzNlQ2ODN5OEK=
CF33 MXLGeY5kfGmxbjDBd5NigQ>? M3S4OlExNTFyMDFOwG0> NVvmTnZXPC1{NDDo NESx[3Jl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R? NGOyTo0zPDVyM{e4Ni=>
LNCaP M1;YUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XxZ|IwPS9zMDFOwG0> MYW5OkBp NYTPdnM2cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NXe1eoM2OjR{OU[5O|g>
LNCaP NYjKdIl1SXCxcITvd4l{KEG|c3H5 MonSNk82NzFyIN88US=> MonIPVYhcA>? NHf3fnVqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NYrlSpdsOjR{OU[5O|g>
PC-3  Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\rN5kxNTVyIN88US=> M2HSOVQ56oDLaB?= M4npS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoDXNlQyOjd6OEK=
PC-3  MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3nlUlAuOTByIN88US=> MV63NkBp M3rt[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkfpNlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 3年-20℃
2年-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

文献中の引用 (6)

Frequently Asked Questions

  • Question 1
    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

    Answer: For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ